Compare AMTD & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTD | PMVP |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.2M | 66.1M |
| IPO Year | 2019 | 2020 |
| Metric | AMTD | PMVP |
|---|---|---|
| Price | $0.83 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.2K | ★ 290.1K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $1.02 |
| 52 Week High | $1.65 | $1.88 |
| Indicator | AMTD | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 49.82 |
| Support Level | $0.71 | $1.04 |
| Resistance Level | $0.80 | $1.26 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 29.95 | 26.67 |
AMTD IDEA Group is a diversified institution and digital solutions conglomerate group, connecting companies and investors with world-wide markets. The group operates its businesses in five reportable and operating segments: capital market solutions segment, digital solutions and other services segment, media and entertainment segment, hotel operations, hospitality and VIP services segment, and strategic investment segment. The group generates the majority of its revenue from the strategic investment segment that engages in proprietary investments and management of world-wide investment portfolio (including listed and unlisted equity shares investments and movie rights investments). Its geographic areas are China, Europe, America, and Southeast Asia.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.